APEX1 and non-small cell lung carcinoma: Moreover, APE1 overexpression was demonstrated to be associated with cisplatin resistance and the addition of gossypol leads to inhibition of APE1 and enhances the activity of cisplatin in non-small cell lung cancer [61,65,66].